Results 31 to 40 of about 29,136 (254)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Infectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu   +3 more
doaj   +1 more source

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Frontiers in Immunology, 2023
Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a second dose of the BioNTech mRNA BNT162b2 vaccine ...
Chang Chu, Anne Schönbrunn, Dorothea Fischer, Yvonne Liu, Yvonne Liu, Johann-Georg Hocher, Jutta Weinerth, Kristin Klemm, Kristin Klemm, Volker von Baehr, Bernhard K. Krämer, Bernhard K. Krämer, Bernhard K. Krämer, Bernhard K. Krämer, Saban Elitok, Saban Elitok, Berthold Hocher, Berthold Hocher, Berthold Hocher   +18 more
doaj   +1 more source

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

International Journal of Infectious Diseases, 2023
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek   +9 more
doaj   +1 more source

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Emerging Microbes and Infections, 2022
Given emerging evidence of immune escape in the SARS-CoV-2 Omicron viral variant, and its dominance, effectiveness of heterologous and homologous boosting schedules commonly used in low-to-middle income countries needs to be re-evaluated.
Jing Lian Suah, Boon Hwa Tng, Peter Seah Keng Tok, Masliyana Husin, Thevesh Thevananthan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +6 more
doaj   +1 more source

Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations

Vaccine, 2021
Heterologous vaccine regimens deliver antigens through different vaccine components or vector types at sequential time points. Clinical development shows promising results and several candidates may be progressing to licensure in the coming years. This study aimed at exploring future acceptance and uptake of such regimens (also called heterologous ...
Helena Greter, Sabrina Ivol, Valérie Oriol Mathieu, Séverine Erismann, Helen Prytherch, Peter Steinmann   +5 more
openaire   +3 more sources

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria

Frontiers in Immunology, 2022
Heterologous immunity, when the memory T cell response elicited by one pathogen recognizes another pathogen, has been offered as a contributing factor for the high variability in coronavirus disease 2019 (COVID-19) severity outcomes.
Peter J. Eggenhuizen, Boaz H. Ng, Janet Chang, Rachel M.Y. Cheong, Anusha Yellapragada, Wey Y. Wong, Yi Tian Ting, Julie A. Monk, Poh-Yi Gan, Poh-Yi Gan, Stephen R. Holdsworth, Stephen R. Holdsworth, Joshua D. Ooi   +12 more
doaj   +1 more source

Pathogenic epitopes, heterologous immunity and vaccine design [PDF]

Nature Reviews Microbiology, 2007
Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic.
Welsh, Raymond M., Fujinami, Robert S.
openaire   +2 more sources

Heterologous prime–boost strategies for COVID-19 vaccines [PDF]

Journal of Travel Medicine, 2021
AbstractBackground/ObjectiveHeterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in ‘Com-Cov2 trial’ in UK, and that of Oxford and Pfizer vaccines in ‘CombivacS trial’ in ...
Binaya Sapkota, Bhuvan Saud, Ranish Shrestha, Dhurgham Al-Fahad, Ranjit Sah, Sunil Shrestha, Alfonso J Rodriguez-Morales   +6 more
openaire   +2 more sources

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

Vaccines, 2022
No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer patients
Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon   +12 more
doaj   +1 more source

Heterologous prime–boost vaccination [PDF]

Current Opinion in Immunology, 2009
An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens.
openaire   +2 more sources